OncoMatch/Clinical Trials/NCT06861244
Embryonal Tumor With Multilayered Rosettes
Is NCT06861244 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Chemotherapy Drug, Cancer - Physician's Choice and Temozolomide for embryonal tumor with multilayered rosettes.
Treatment: Chemotherapy Drug, Cancer - Physician's Choice · Temozolomide — This is an open-label, comprehensive, iterative investigation of evaluating the use of induction chemotherapy, high-dose chemotherapy, and focal radiation therapy in children with newly diagnosed Embryonal Tumor With Multilayered Rosettes (ETMR).
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: radiation therapy
Participants must not have received prior radiation for treatment of tumor.
Cannot have received: tumor-directed therapy (other than surgical resection)
Exception: Cohort 1 only
Cohort 1 participants must not have received any prior tumor-directed therapy other than surgical resection.
Cannot have received: tumor directed investigational agents
Participants who are receiving any other tumor directed investigational agents.
Lab requirements
Blood counts
Peripheral absolute neutrophil count (ANC) > 75,000/mm3; Platelet count > 75,000/mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 72 hours prior to enrollment)
Kidney function
Serum creatinine < 1.5 x ULN based on age and gender
Liver function
Total bilirubin < 1.5 x ULN for age; in presence of Gilbert's syndrome, total bilirubin < 3 x ULN or direct bilirubin < 1.5 x ULN; ALT < 3 x ULN; AST < 3 x ULN
Organ Function Requirements: Peripheral absolute neutrophil count (ANC) > 75,000/mm3; Platelet count > 75,000/mm3 (transfusion independent, defined as not receiving platelet transfusions for at least 72 hours prior to enrollment). Adequate Renal Function defined as: Serum creatinine < 1.5 x upper limit normal (ULN) based on age and gender. Adequate Liver Function defined as: Total bilirubin < 1.5 x upper limit of normal (ULN) for age; in presence of Gilbert's syndrome, total bilirubin < 3 x ULN or direct bilirubin < 1.5 x ULN, ALT < 3 x ULN, AST < 3 x ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- University of California, San Francisco · San Francisco, California
- Riley Hospital for Children at Indiana University Health · Indianapolis, Indiana
- Johns Hopkins University · Baltimore, Maryland
- Washington University in St. Louis · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify